View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
April 30, 2022

Medical Devices industry M&A deals total $320.6m globally in March 2022

By Carmen

Total medical devices industry M&A deals worth $320.6m were announced globally in March 2022, led by Fresenius Kabi’s $240m acquisition of Ivenix, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 0.3% over the previous month of $321.51m and a drop of 95.9% when compared with the last 12-month average, which stood at $7.88bn.

Comparing M&A deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $240m. At the country level, the US topped the list in terms of deal value at $240m.

In terms of volumes, Europe emerged as the top region for medical devices industry M&A deals globally, followed by North America and then Asia-Pacific.

The top country in terms of M&A deals activity in March 2022 was the US with 11 deals, followed by the UK with four and Japan with three.

In 2022, as of March, medical devices M&A deals worth $7.12bn were announced globally, marking an increase of 73.9% year on year.

medical devices industry M&A deals in March 2022: Top deals

The top five M&A deals accounted for 100% of the overall value during March 2022.

The combined value of the top five medical devices M&A deals stood at $320.55m, against the overall value of $320.6m recorded for the month.

The top five medical devices industry M&A deals of March 2022 tracked by GlobalData were:

1) Fresenius Kabi $240m acquisition deal with Ivenix

2) The $24.35m acquisition of LDPath by SourceBio International

3) BioKey and ImmunoPrecise Netherlands $21.94m acquisition deal with BioClue and BioStrand

4) The $21.06m acquisition of Sinusafe Medical by Bold Capital Enterprises

5) SD Biosensor $13.2m acquisition deal with bestbion dx

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU